NTLA Intellia Therapeutics Inc
Company Analysis
Latest News
🔴 NTLA is trading 7.6% down today amid a weaker equity backdrop
NTLA is trading at $14.71 (7.6% down) in pre-market action as index futures point lower and broader market risk appetite softens. • The move follows a...
🟢 Intellia Therapeutics Inc makes sharp 10.7% jump
NTLA is trading at $16.10, up 10.7% versus the comparison close of $14.55 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 Intellia Therapeutics Inc is trading 5.84% up today as it extends gains from positive CRISPR trial data
Intellia Therapeutics Inc is trading at $15.40 (+5.84%) today, extending a sharp upward move sparked by recent positive CRISPR trial data. • The stock...
Intellia's Gene-Editing Breakthrough Sparked a 23% Rally — But Can a $2 Billion Biotech Sustain the Momentum on a Single Drug?
Shares of Intellia Therapeutics sank 8.8% to $13.61 on June 16, giving back a chunk of the prior session's 23.2% spike — a textbook profit-taking selloff after...
🔴 Intellia Therapeutics Inc is trading 8.8% down today on profit-taking after a Phase 3 data-driven surge
Intellia Therapeutics Inc is trading at $13.61, down 8.8% today, as the stock pulls back and consolidates following a sharp rally in the previous session. •...
🟢 Intellia Therapeutics Inc makes sharp 14.8% jump
NTLA is trading at $13.90, up 14.8% versus the comparison close of $12.11 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 Intellia Therapeutics Inc is trading 10.2% up today after positive Phase 3 HAELO trial results for HAE therapy
Intellia Therapeutics Inc is trading 10.2% up at $13.35 after releasing additional positive Phase 3 HAELO trial results for its hereditary angioedema...
Intellia Reports Positive Phase 3 Trial Results for HAE Therapy Lonvo-z
Intellia Therapeutics announced additional positive results from its global Phase 3 HAELO clinical trial for lonvoguran ziclumeran (lonvo-z), a single-dose...
🟢 Intellia Therapeutics Inc is trading 5% up today after positive Phase 3 HAELO trial results for lonvo-z
Intellia Therapeutics Inc is trading 5% up at $12.72 in pre-market, rebounding after recent weakness following the disclosure of positive clinical data. • The...
Intellia Reports 87% Drop in HAE Attacks, Meeting Phase 3 Endpoints
Intellia Therapeutics announced positive results from the global Phase 3 HAELO clinical trial of lonvo-z for hereditary angioedema (HAE). The European Academy...
🔴 Intellia Therapeutics Inc is trading 5% down today on post-earnings weakness and dilution concerns
Intellia Therapeutics Inc is trading about 5% down today around the mid-$12s, extending a decline following its recent quarterly update and equity...
🔴 Intellia Therapeutics Inc is trading 5.1% down today amid post-earnings repositioning and dilution concerns
Intellia Therapeutics Inc is trading 5.1% down at $12.80 as investors continue to reassess the company's fundamentals following recent financial results and...
🔴 Intellia Therapeutics Inc is trading 10.51% down today as investors take profits amid broader market weakness and cash-burn concerns
Intellia Therapeutics Inc is trading at $13.20 (-10.51%) as investors lock in gains following a recent rally, while broader market pressure and cash-burn risks...
🔴 Intellia Therapeutics Inc is trading 8.6% down today on profit-taking and renewed focus on cash burn and dilution
Intellia Therapeutics Inc is trading at $13.47 (8.6% down) as investors lock in profits following yesterday’s 13% surge and shift focus back to the company's...
Intellia Pops 13.5% on Earnings-Beat Signal — But Can a Pre-Revenue Biotech Justify Its $1.8 Billion Price Tag?
Shares of Intellia Therapeutics surged 13.5% to $14.77 after a Zacks research note flagged the CRISPR gene-editing firm as statistically likely to beat Wall...
🟢 Intellia Therapeutics Inc is trading 13.5% up today on bullish research and expected EPS beat
Intellia Therapeutics Inc is trading 13.5% up today at $14.77 as investors react to fresh bullish research from Zacks ahead of the company's upcoming earnings...